
CLAIMS

What is claimed is:


1. A compound of Formula 1A:



Formula 1A

or a pharmaceutically acceptable salt thereof, wherein:

R^1 is:



, wherein:

E is present, and is selected from the group consisting of H, halo, OH, CN, -O(C_1-C_6)alkyl, -(C_1-C_6)alkyl, -C(O)OH, -C(O)$NR^8R^{8'}$, -(C_1-C_6)alkyl-C(O)OH, -(C_1-C_6)alkyl-OH, -(C_1-C_6)alkyl-C(O)$NR^8R^{8'}$, -(C_2-C_6)alkenyl, -(C_2-C_6)alkynyl, heterocyclyl, and heteroaryl;

each J independently is selected from the group consisting of H and halogen;

Y and R may or may not be present, when Y is present, it is selected from the group consisting of O, S, NR^8, SO_2, and $CR^8R^{8'}$;

R when present is one or more moieties independently selected from the group consisting of -(C_1-C_6)alkyl, and –($CR^8R^{8'}$)$_n$-C(O)OH;



G is present and is selected from the group consisting of–($CR^8R^{8'}$)$_n$-(C_3-C_8)cycloalkyl-($CR^8R^{8'}$)$_n$-C(O)OH, and –($CR^8R^{8'}$)$_n$-O–($CR^8R^{8'}$)$_n$-(C_3-C_8)cycloalkyl-($CR^8R^{8'}$)$_n$-C(O)OH;

~~; wherein:~~



each R^8 and $R^{8'}$ is independently selected from the group consisting of H, Deuterium (D), and $(C_1\text{-}C_6)$alkyl; or wherein R^8 and $R^{8'}$ together with the carbon to which each is attached form $(C_3\text{-}C_8)$cycloalkyl;

~~each R^9 independently is $SO_2(C_1\text{-}C_6)$alkyl or $SO_2(C_3\text{-}C_8)$cycloalkyl;~~

each n independently is 0-10; ~~providing~~ provided that when n is 0, any oxygen, nitrogen or sulfur atom of Y is not directly linked to any oxygen, nitrogen, sulfur or phosphorus atom of G;

R^2 is  ~~or~~ ;

~~R^4, $R^{4'}$,~~ R^5, $R^{5'}$, R^6, $R^{6'}$, R^7, and $R^{7'}$ independently are selected from the group consisting of hydrogen and $(C_1\text{-}C_6)$alkyl; and

X is  or 

2. The compound of claim 1, wherein E is present and is selected from the group consisting of H, halo, OH, CN, $-O(C_1\text{-}C_6)$alkyl, $(C_1\text{-}C_6)$alkyl, -C(O)OH, $-C(O)NR^8R^{8'}$, $-(C_1\text{-}C_6)$alkyl-C(O)OH, $-(C_1\text{-}C_6)$alkyl-OH, $-(C_1\text{-}C_6)$alkyl-$C(O)NR^8R^{8'}$, and heteroaryl.

3. The compound of claim 2, wherein said $-(C_1\text{-}C_6)$alkyl-OH is hydroxymethyl; said ~~$(C_1\text{-}C_6)$alkyl~~-$C(O)NR^8R^{8'}$ is $-C(O)NH_2$; said $-(C_1\text{-}C_6)$alkyl-

C(O)OH is $-(CH_2)_4COOH$; said halo is –F; said $-O(C_1-C_6)$alkyl is methoxy; said $-(C_1-C_6)$alkyl is methyl; and said heteroaryl is tetrazolyl.

4. The compound of claim 1, wherein each J independently is H or Fluoro.

5. The compound of claim 1, wherein Y is present and is selected from the group consisting of O, S, SO_2, and $CR^8R^{8'}$.


6. The compound of claim 1, wherein in G, said $-(CR^8R^{8'})_n-(C_3-C_8)$cycloalkyl-$(CR^8R^{8'})_n$-C(O)OH is selected from the group consisting of $-CH_2$-cyclopentyl-C(O)OH, -cyclobutyl-C(O)OH, -cyclopentyl-C(O)OH, -cyclohexyl-C(O)OH, and -cyclopentyl-CH_2-C(O)OH; said $-(CR^8R^{8'})_n-O-(CR^8R^{8'})_n-(C_3-C_8)$cycloalkyl-$(CR^8R^{8'})_n$-C(O)OH is –O-cyclopentyl-C(O)OH or –O-cyclobutyl-C(O)OH.

7. The compound of claim 1, wherein Y is O and G is $-(CR^8R^{8'})_n-(C_3-C_8)$cycloalkyl-$(CR^8R^{8'})_n$-C(O)OH.

8. The compound of claim 1, wherein Y is S and G is $-(CR^8R^{8'})_n-(C_3-C_8)$cycloalkyl-$(CR^8R^{8'})_n$-C(O)OH.

9. The compound of claim 1, wherein Y is $CR^8R^{8'}$ and G is $-(CR^8R^{8'})_n-O-(CR^8R^{8'})_n-(C_3-C_8)$cycloalkyl-$(CR^8R^{8'})_n$-C(O)OH.

~~10. The compound of claim 1, wherein R^4 is hydrogen and $R^{4'}$ is 1-propyl, such that Formula 1 is represented by Formula 1A:~~




~~Formula 1A~~

~~wherein R^1, R^2, R^5, $R^{5'}$, R^6, $R^{6'}$, R^7, $R^{7'}$, and X are as set forth in Formula 1.~~


10~~11~~. The compound of claim ~~10~~1, wherein R^5, $R^{5'}$, R^6, $R^{6'}$, R^7, and $R^{7'}$ are all hydrogen.


11~~12~~. The compound of claim ~~11~~1, wherein:

~~R^2 is~~  ~~; and~~

either (i) each J in R^1 is H, or (ii) one J in R^1 is halo, and the remaining three Js are H.


12~~13~~. The compound of claim ~~12~~1, wherein:

~~R^1 is~~  ~~;~~


 ~~R^2 is~~ ~~; and~~

each J in R^1 is H.


~~14~~13. A compound selected from the group consisting of:




,




,







,




,




,




,





,





,



N
F
F
F
O
N
O
O
O
OH
N
O
N
F
F
F

















,




,




,




,




,




,




,




,




,




,




,




,








,





,




,


,

,

,

,

,






,




,and


F
F
F
S
O
O
N
O
O
N
O
F
F
F
N
O
OH

;


or a pharmaceutically acceptable salt thereof.


~~15.~~ 14. ~~The~~ A compound ~~of claim 14~~ that is



or a pharmaceutically acceptable salt thereof.


~~16.~~ 15. ~~The~~ A compound ~~of claim 14~~ that is






or a pharmaceutically acceptable salt thereof.


~~17.~~ 16. ~~The~~ A compound ~~of claim 14~~ that is






or a pharmaceutically acceptable salt thereof.


~~18.~~17. ~~The~~ A compound ~~of claim 14~~ that is



or a pharmaceutically acceptable salt thereof.

~~19.~~18. ~~The~~ A compound ~~of claim 14~~ that is





or a pharmaceutically acceptable salt thereof.

15. 19. A pharmaceutical composition comprising a therapeutically effective amount of at least one compound of any one of claims 1 to ~~19~~ 18 or a pharmaceutically acceptable salt thereof, in combination with at least one pharmaceutically acceptable carrier.

~~16.~~20 Use of a compound of any one of claims 1 to ~~19~~ 18 for

the preparation of a medicament for the treatment of cancer selected from the group consisting of colorectal, bladder, breast, colon, rectum, endometrium, kidney, liver, lung, head and neck, esophagus, gall bladder, cervix, pancreas, prostrate, larynx, ovaries, stomach, uterus, Non-Hodgkin's lymphoma, sarcoma, osteosarcoma, liposarcoma, thyroid cancer, hematopoietic tumors of the lymphoid lineage, hematopoetic tumors of myeloid lineage, myelogenous leukemias, myelodysplastic syndrome, promyelocytic leukemia, tumors of mesenchymal origin, tumors of the central and peripheral nervous system, melanoma, skin ~~(non-melanomal)~~ cancer, mesothelioma ~~(cells)~~, seminoma, teratocarcinoma, xenoderoma pigmentosum, keratoctanthoma, glioblastoma, acute myeloid leukemia, acute lymphoblastic leukemia, thyroid follicular cancer and Kaposi's sarcoma.